Deng C-Y, Wang X-F, Qi H, Li F-R
The Key Laboratory of stem cell and Cellular therapy, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, China.
Scand J Immunol. 2016 Aug;84(2):86-94. doi: 10.1111/sji.12446.
Anti-CD45RB monoclonal antibody (anti-CD45RBmAb), as a new immune tolerance inducer, may inhibit T cell proliferation and induce immune tolerance through competitive combination with CD45RB on the T cell surface, which blocks the conduction of activation signals. However, how anti-CD45RBmAb plays its role on T lymphocyte subsets during immunosuppression remains unclear. In this work, we investigate the effects of anti-CD45RBmAb on CD3(+) T lymphocyte both in vitro and in allogeneic heart transplant model in vivo. Interestingly, anti-CD45RBmAb could inhibit the proliferation of T cells, promote the transformation of T lymphocyte to Treg and Th2 cells, suppress the transformation to Th17 and Th1 cells, increase the number of Ts cells, decrease the number of Tm cells and thus play a role in immune inhibition and induction of immune tolerance.
抗CD45RB单克隆抗体（抗CD45RBmAb）作为一种新型免疫耐受诱导剂，可能通过与T细胞表面的CD45RB竞争性结合来抑制T细胞增殖并诱导免疫耐受，从而阻断激活信号的传导。然而，抗CD45RBmAb在免疫抑制过程中如何作用于T淋巴细胞亚群仍不清楚。在本研究中，我们在体外和体内同种异体心脏移植模型中研究了抗CD45RBmAb对CD3(+) T淋巴细胞的影响。有趣的是，抗CD45RBmAb可抑制T细胞增殖，促进T淋巴细胞向Treg和Th2细胞转化，抑制向Th17和Th1细胞转化，增加Ts细胞数量，减少Tm细胞数量，从而发挥免疫抑制和诱导免疫耐受的作用。
Zotero 插件